CytomX Therapeutics
(NASDAQ) CTMX
CytomX Therapeutics Financials at a Glance
Market Cap
$918.75M
Revenue (TTM)
$76.20M
Net Income (TTM)
$17.37M
EPS (TTM)
$0.01
P/E Ratio
467.03
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Price
$4.25
Volume
133,251
Open
$4.50
Price
$4.25
Volume
133,251
Open
$4.50
Previous Close
$4.25
Daily Range
$4.18 - $4.50
52-Week Range
$0.48 - $8.21
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Price
$4.25
Volume
133,251
Open
$4.50
Previous Close
$4.25
Daily Range
$4.18 - $4.50
52-Week Range
$0.48 - $8.21
CTMX News
CTMX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout CytomX Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
69
CEO
Sean A. McCarthy, PhD, MBA
Website
www.cytomx.comHeadquarters
South San Francisco, CA 94080, US
CTMX Financials
Key Financial Metrics (TTM)
Gross Margin
99%
Operating Margin
-29%
Net Income Margin
-23%
Return on Equity
-35%
Return on Capital
-21%
Return on Assets
-11%
Earnings Yield
0.21%
Dividend Yield
0.00%
Payout Ratio
-17.28%
Stock Overview
Market Cap
$918.75M
Shares Outstanding
216.18M
Volume
133.25K
Short Interest
0.00%
Avg. Volume
6.80M
Financials (TTM)
Gross Profit
$76.20M
Operating Income
$19.56M
EBITDA
$18.19M
Operating Cash Flow
$75.59M
Capital Expenditure
$220.00K
Free Cash Flow
$75.81M
Cash & ST Invst.
$137.05M
Total Debt
$4.24M
CytomX Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$663.00K
-98.3%
Gross Profit
$153.00K
-99.6%
Gross Margin
23.08%
N/A
Market Cap
$918.75M
N/A
Market Cap/Employee
$7.72M
N/A
Employees
119
N/A
Net Income
$26.51M
-240.4%
EBITDA
$27.42M
-251.6%
Quarterly Fundamentals
Net Cash
$132.81M
+45.6%
Accounts Receivable
$2.51M
-19.0%
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$4.24M
-17.6%
Return on Assets
-11.39%
N/A
Return on Invested Capital
-21.12%
N/A
Free Cash Flow
$23.44M
-17.3%
Operating Cash Flow
$23.24M
-16.8%